Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 20/20 | 0.42 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.41 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | SCN1A | P35498 | 1/20 | 0.41 |
| ▸ | SCN4A | P35499 | 1/20 | 0.41 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.41 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.41 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.41 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL832811 | 0.88 | TP53 (0.43) | — | |
| SCHEMBL832949 | 0.85 | KMT2A (0.40) | — | |
| SCHEMBL13395482 | 0.84 | SCN9A (0.36) | SCN9ASCN5AABCB11CYP2C9SCN1A | |
| SCHEMBL862210 | 0.82 | CYP2C8 (0.46) | SCN9ASCN5A | |
| SCHEMBL14802301 | 0.81 | SCN9A (0.42) | SCN9ASCN5AABCB11CYP2C9SCN1A | |
| SCHEMBL862647 | 0.81 | EDNRB (0.41) | SCN9ASCN5AABCB11CYP2C9SCN1A | |
| SCHEMBL14802293 | 0.80 | PPARG (0.39) | SCN9ASCN5ACYP2C9 | |
| SCHEMBL831658 | 0.77 | PPARG (0.48) | — | |
| SCHEMBL862252 | 0.77 | SCN9A (0.38) | SCN9ASCN5AABCB11CYP2C9SCN1A | |
| SCHEMBL13395460 | 0.76 | SCN9A (0.40) | SCN9ASCN5AABCB11CYP2C9SCN1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143305-B2 | 2,3-substituted indole derivatives for treating viral infections | SCHERING CORPORATION (US) | 2012-03-27 | — | — | US | disclosed |
| US-20110033417-A1 | 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | MERCK SHARP & DOHME CORP. | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110033417-A1 | 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | IDO2, IDO1, IRF3 | SCN9A 3807/4885SCN5A 1398/4885ABCB11 4100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.